Key facts
- This page summarizes Gregory Oakes's Form 4 filing for First Wave BioPharma, Inc. (ENTO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Jan 2022, 20:07.
Gregory Oakes - 03 Jan 2022 Form 4 Insider Report for First Wave BioPharma, Inc. (ENTO)
- Reporting relationship
- Director
- Issuer ticker
- ENTO
- Reported as of
- 03 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jan 2022, 20:07:12 UTC
- Next SEC filing
- 22 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gregory Oakes
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Gregory Oakes filed Form 4 for First Wave BioPharma, Inc. (ENTO) on 03 Jan 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FWBI
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +34,482
- Change %
- Price
- $0.000000
- Shares after
- 34,482
- Date
- 03 Jan 2022
- Ownership
- Direct
- Underlying class
- Common stock, par value $0.0001 per share
- Underlying amount
- 34,482
- Exercise price
- $1.45
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option vests in equal quarterly installments on each of March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022.